著者
Masahiro Natsuaki Takeshi Morimoto Hiroki Shiomi Ko Yamamoto Kyohei Yamaji Hirotoshi Watanabe Takashi Uegaito Mitsuo Matsuda Toshihiro Tamura Ryoji Taniguchi Moriaki Inoko Hiroshi Mabuchi Teruki Takeda Takenori Domei Manabu Shirotani Natsuhiko Ehara Hiroshi Eizawa Katsuhisa Ishii Masaru Tanaka Tsukasa Inada Tomoya Onodera Ryuzo Nawada Eiji Shinoda Miho Yamada Takashi Yamamoto Hiroshi Sakai Mamoru Toyofuku Takashi Tamura Mamoru Takahashi Tomohisa Tada Hiroki Sakamoto Takeshi Tada Kazuhisa Kaneda Shinji Miki Takeshi Aoyama Satoru Suwa Yukihito Sato Kenji Ando Yutaka Furukawa Yoshihisa Nakagawa Kazushige Kadota Takeshi Kimura on behalf of the CREDO-Kyoto PCI/CABG Registry Cohort-Investigators
出版者
The Japanese Circulation Society
雑誌
Circulation Journal (ISSN:13469843)
巻号頁・発行日
pp.CJ-21-0526, (Released:2021-09-16)
参考文献数
27
被引用文献数
1

Background:Optimal intensity is unclear for P2Y12receptor blocker therapy after percutaneous coronary intervention (PCI) in real-world clinical practice.Methods and Results:From the CREDO-Kyoto Registry, the current study population consisted of 25,419 patients (Cohort-2: n=12,161 and Cohort-3: n=13,258) who underwent their first PCI. P2Y12receptor blocker therapies were reduced dose of ticlopidine (200 mg/day), and global dose of clopidogrel (75 mg/day) in 87.7% and 94.8% of patients in Cohort-2 and Cohort-3, respectively. Cumulative 3-year incidence of GUSTO moderate/severe bleeding was significantly higher in Cohort-3 than in Cohort-2 (12.1% and 9.0%, P<0.0001). After adjusting 17 demographic factors and 9 management factors potentially related to the bleeding events other than the type of P2Y12receptor blocker, the higher bleeding risk in Cohort-3 relative to Cohort-2 remained significant (hazard ratio (HR): 1.52 95% confidence interval (CI) 1.37–1.68, P<0.0001). Cohort-3 compared with Cohort-2 was not associated with lower adjusted risk for myocardial infarction/ischemic stroke (HR: 0.96, 95% CI: 0.87–1.06, P=0.44).Conclusions:In this historical comparative study, Cohort-3 compared with Cohort-2 was associated with excess bleeding risk, which might be at least partly explained by the difference in P2Y12receptor blockers.
著者
Yukiko SHOUJI Chika HASEGAWA Xiao-Pen LEE Masaya FUJISHIRO Takaaki MATSUYAMA Miho YAMADA Ayako KURIKI Yuka KATO Noriko NEMOTO Takeshi KUMAZAWA Shinichi SUZUKI Keizo SATO
出版者
The Showa University Society
雑誌
The Showa University Journal of Medical Sciences (ISSN:09156380)
巻号頁・発行日
vol.30, no.2, pp.175-187, 2018 (Released:2018-08-31)
参考文献数
33
被引用文献数
1

A high-throughput method was developed to analyze five barbiturates (phenobarbital, cyclobarbital, amobarbital, secobarbital, and thiopental) and a metabolite in human body samples using a new Monolithic C18 gel-packed Spin Tip and ultra-performance liquid chromatography (UPLC)-quadrupole-time-of-flight (Q-ToF) mass spectrometry (MS). Plasma (20µl) or urine (100µl) samples spiked with the five barbiturates and 5-(4-methylphenyl)-5-phenylhydantoin (internal standard, IS) were mixed with distilled water. The mixture was extracted using the Monolithic C18 Spin Tip, and the analytes retained on the C18 phase were then eluted with methanol. The eluate was injected directly into an analytical column (Waters Acquity BEH C18, 50mm×2.1mm i.d., particle size 1.7µm), and quantified by Q-ToF-MS with negative-ion electrospray ionization (ESI). Good separation and clear peak shapes of the five drugs were achieved within an analysis time of 6min, including the extraction time. All drugs spiked in the plasma showed recoveries of 86-98%. The regression equations for the five drugs showed excellent linearities in the range of 5-500ng/20µl of plasma, with limits of detection and i-Fit of 1ng/20µl. The method was also successfully applied to determine the level of amobarbital and its metabolite in human plasma and urine, respectively, after oral administration to a volunteer. This new method could be applied widely in the clinical and forensic fields for the quantitative determination of drugs and metabolites.